妊娠期宫颈癌新辅助化疗后残留病灶的MRI评估
回顾性单中心研究纳入2010至2021年12例接受铂类新辅助化疗的妊娠期宫颈癌患者,于化疗前后行MRI评估肿瘤最大径及淋巴结状态,以根治性子宫切除术后病理为参考标准计算MRI诊断残留病灶的效能。MRI敏感度100.0%、特异度66.7%、准确率91.7%,提示MRI对该人群化疗后残留病灶检测具有良好诊断效能,可能用于评估治疗反应。
要点
- 妊娠期宫颈癌新辅助化疗后MRI评估残留病灶敏感度100.0%、准确率91.7%。
- MRI无残留病灶者与病理全部一致,有残留病灶者10例中9例与病理一致。
- 特异度66.7%(95%CI 0.13–1.00),阴性病例仅2例,需注意假阳性可能。
核心结论
- 作者认为MRI在检测妊娠期宫颈癌患者新辅助化疗后残留病灶方面具有良好诊断效能,可能用于评估该情形下的治疗反应。
研究设计与样本
- 回顾性单中心研究,纳入2010至2021年连续接受铂类新辅助化疗并在治疗方案前及结束时行MRI检查的妊娠期宫颈癌患者12例(中位年龄36岁,范围27–42岁),以根治性子宫切除术后组织病理学为参考标准。
关键影像表现/征象
- 新辅助化疗后MRI评估肿瘤最大径及淋巴结状态,化疗后肿瘤负荷增加者被排除;化疗后MRI显示2/12例(16.7%)无残留病灶、10/12例(83.3%)有残留病灶。
诊断标准与关键数值
- MRI检测残留病灶的敏感度100.0%(95%CI 1.00–1.00)、特异度66.7%(95%CI 0.13–1.00)、阳性预测值90%(95%CI 0.71–1.00)、阴性预测值100%(95%CI 1.00–1.00)、准确率91.7%(95%CI 0.76–1.00),P=0.045。
临床应用与阅片要点
- 阅片时于新辅助化疗前后分别评估肿瘤最大径与淋巴结状态,化疗后肿瘤负荷增加者不纳入残留病灶评估;MRI无残留病灶者与病理全部一致,有残留病灶者10例中1例与病理不一致。
局限性
- 原文为回顾性单中心研究。
- 样本量小,仅纳入12例妊娠患者。
- 特异度95%CI为0.13–1.00,区间宽。
- 作者结论使用suggests、potentially等限定语气。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: This study explores the performance of MRI in detecting residual disease after platinum-based neoadjuvant chemotherapy (NACT) in pregnant cervical cancer (CC) patients, which would serve as a surrogate of treatment response.
METHODS: In this retrospective single-centre study, consecutive pregnant cervical cancer patients treated with NACT and undergoing MRI examination before and at the end of the therapeutic protocol between 2010 and 2021 were included. Tumour maximum diameter and nodal status were evaluated in MRI at staging and after NACT. Patients exhibiting increased tumor burden post-NACT were excluded. On post-NACT the presence or absence of residual disease was recorded and the MRI diagnostic performance for assessing residual disease was calculated using histopathology at radical hysterectomy as the reference standard.
RESULTS: The study included 12 pregnant patients (median age 36 years, 27-42). At post-NACT MRI, residual disease was absent in 2/12 patients (16.7 %) while present in 10/12 (83.3 %). Histopathology was concordant in all patients without MRI residual disease and in 9/10 patients with MRI residual disease, while discordant in 1/10. MRI sensitivity, specificity, positive predictive value, negative predictive and accuracy for detecting residual disease were 100.0 % (95 %CI: 1.00, 1.00), 66.7 % (95 %CI: 0.13, 1.00), 90 % (95 %CI: 0.71, 1.00), 100 % (95 %CI: 1.00, 1.00), and 91.7 % (95 %CI: 0.76, 1.00) respectively (p = 0.045).
CONCLUSIONS: This study suggests that MRI has good diagnostic performance to detect residual disease after NACT in pregnant CC patients, and potentially assess response to treatment in this setting.
引用
- Russo L, D'Erme L, Bottazzi S, et al. MRI-based assessment of residual disease after neoadjuvant chemotherapy in pregnant women with cervical cancer. Eur J Radiol. 2024. PMID: 39509748. doi:10.1016/j.ejrad.2024.111766
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。